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Objectives: Delayed-release dimethyl fumarate (DMF; also known as gastro-
resistant DMF) and fingolimod are oral disease-modifying treatments for relaps-
ing-remitting multiple sclerosis (RRMS). Direct comparisons of these agents are 
not possible due to a lack of head-to-head trials. In this study, comparative effec-
tiveness research was conducted by indirectly comparing efficacy outcomes at 2 
years with DMF or fingolimod treatment of RRMS in Phase 3 studies. MethOds: 
Individual patient data from the DEFINE and CONFIRM studies of DMF (pooled) 
and aggregate data from the FREEDOMS and FREEDOMS II studies of fingolimod 
(pooled using random effects meta-analysis) were utilised. Only results using the 
approved dosage of DMF (240 mg twice daily) and fingolimod (0.5 mg once daily) 
are reported. Matching-adjusted indirect comparison was conducted as described 
in Signorovitch et al (2010). Patients in the pooled DMF trials were weighted such 
that their average baseline characteristics (age, gender, time from onset of symp-
toms, Expanded Disability Status Scale score, number of relapses in previous year) 
matched those reported for patients in pooled fingolimod trials. After matching, 
weighted efficacy outcomes for patients treated with DMF were compared with 
summary efficacy outcomes for patients treated with fingolimod. Results: After 
matching, all baseline characteristics were balanced between the pooled DMF tri-
als and the pooled fingolimod trials. At 2 years, annualised relapse rate ratio (95% 
confidence interval [CI]) for DMF vs placebo was 0.52 (0.43, 0.62) and for fingolimod 
vs placebo was 0.48 (0.42, 0.55). Twelve-week confirmed disease progression hazard 
ratio (95% CI) for DMF vs placebo was 0.70 (0.57, 0.85) and for fingolimod vs placebo 
was 0.76 (0.61, 0.95). Additional data, including comparison of DMF vs fingolimod, 
will be presented. cOnclusiOns: In a matching-adjusted indirect comparison, the 
efficacy of DMF was similar to that of fingolimod on clinical measures of relapse 
and disability progression.
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Objectives: Relapses and disability progression are the clinical hallmarks of MS 
and the two most commonly assessed endpoints for therapeutic interventions in 
clinical trials. For many patients relapses are the initial defining feature of MS. 
However, the accumulation of disability has the greatest long-term clinical, social 
and economic impact on patients and society. This study evaluated the compara-
tive efficacy of disease-modifying therapies for multiple sclerosis and ranked 
each therapy based on probabilities of being among the best treatments for each 
outcome. MethOds: A network meta-analysis was conducted within a Bayesian 
framework to estimate comparative annualised relapse rates (ARR) and risks of 
disability progression (defined by both a 3-month, and 6-month confirmation 
interval). Cumulative ranking analysis, using the Surface Under the Cumulative 
RAnking curve (SUCRA) method, provided a ranking of treatments for each out-
come. Results: Alemtuzumab and natalizumab had the highest SUCRA scores 
for ARR (> 90%) and disability progression confirmed after three months (> 80%), 
while IFN β -1a 30mcg ranked lowest among active treatments for these outcomes. 
Ranking of treatments was affected by the definition of disability progression largely 
due to the conflicting results of IFN β -1b 250 mcg, ranking among the most effi-
cacious treatments for disability progression confirmed after six months (> 90%) 
and among the least efficacious for disability progression confirmed after three 
months (< 50%). Alemtuzumab and natalizumab both scored relatively highly for 
disability progression confirmed after six months. Notable variation in ranking 
across outcomes was observed for fingolimod (> 70% for ARR, < 50% for the disability 
progression outcomes). cOnclusiOns: The magnitude of treatment effects and 
associated uncertainty varied between DMTs, and across outcomes. While natali-
zumab and alemtuzumab demonstrated consistently high ranking for both relapse 
and progression, with older interferon-beta and glatiramer acetate products ranking 
lowest, variation in disability progression definitions lead to variation in the relative 
ranking of treatments.
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Objectives: Neuromyelitis Optica (NMO) has been described as a disease clinically 
characterised by severe optic neuritis and transverse myelitis. There are very few 
epidemiological studies in NMO and no randomised controlled studies that guide 
therapy. The aim of this review is to determine epidemiology of NMO and to provide 
an algorithm of treatment. MethOds: A systematic search was conducted of the 
relevant published evidence from Embase, MEDLINE, and Cochrane. Search limits 
were articles in English and in human. Retrieved citations were screened by two 
independent reviewers according to inclusion criteria: NMO, incidence, prevalence, 
and treatments reported in population base and observational studies. The analy-
ses of comparable outcomes were carried out as per appropriate statistics along 
with critical appraisal of the studies. Results: A total 16 studies met the inclusion 
criteria including six studies reported epidemiological data while 10 other studies 
reported treatment algorithm. Incidence of NMO ranged from 0.05 per 100,000 per 
year in United Kingdom (UK) to 0.4 per 100,000 in Southern Denmark. Prevalence 
was ranged from 0.44 per 100,000 in UK to 4.4 per 100,000 in Southern Denmark. 
Peak prevalence of NMO occurs among the people at 40-49 years of age. Low level 
evidence recommended methylprednisolone 1g/day for 3 to 5 days or 2 to 3 ses-
sions of plasmapheresis per week, up to 7 sessions for acute attacks of NMO. Nine 
studies observed the improvements in the reduction of mean annualized relapse 
rate. cOnclusiOns: There is limited evidence on current available treatment thera-
pies for NMO. The available low level evidence found that high dose intravenous 
and overseas databases including Ovid-MEDLINE, Ovid-EMBASE and Cochrane 
Library. Total of 274 studies were searched and 6 studies were included in the final 
assessment. Each of the stages from literature search and extraction of data were 
carried out independently by 2 researchers. Results: The effectiveness of CBL 
gene mutation test was assessed by CBL gene mutation detection rate, relevance 
between CBL gene mutation and clinical symptoms, and impact on medical deci-
sions. The CBL gene mutation detection rate was 5 to 19% among JMML patients. The 
hemoglobin level and age-at-diagnosis were both significantly low among patients 
with a CBL gene mutation (p= .02, p= .037). There was intent to assess the impact 
of detecting CBL gene mutation on the medical decisions such as changes in the 
treatment plan and/or method; however, there were no studies reporting on this 
matter. cOnclusiOns: There is a need for quick and accurate diagnosis for JMML, 
which is an intractable disease occurring in childhood, and the test in question 
can be helpful in deciding on stem cell transplantation. Also, considering that CBL 
gene mutation occurs exclusively from other gene mutations (PTPN11, RAS, NF1, 
etc.) causing JMML, it was deemed that even a low detection rate of 5 to 19% had a 
clinical significance. The CBL gene mutation test is an effective test that can con-
tribute to the diagnosis of JMML and help determine the treatment strategy (Grade 
of recommendation: C).
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Objectives: To compare confirmed disability improvement in propensity score 
(PS)-matched cohorts of patients receiving fingolimod or BRACE (beta-interferons 
or glatiramer acetate) following previous BRACE treatment, who had active multiple 
sclerosis (MS), using data from two German observational studies, PANGAEA and 
PEARL, respectively. MethOds: Patients with active MS (≥ 1 relapse in the year 
before the study) from the PANGAEA and PEARL registries were included if they 
had received BRACE before participating in the studies and did not have miss-
ing relapse data in the previous year. Patients from the PANGAEA registry were 
excluded if they had participated in PEARL. Patients in the PANGAEA cohort 
were matched in a 3:1 ratio to patients in the PEARL cohort using a PS-matching 
approach. Time to 3-month and 6-month confirmed disability improvement was 
assessed using a Kaplan–Meier approach. Hazard ratios for confirmed disability 
improvement (fingolimod vs BRACE) were estimated using a Cox proportional haz-
ards model. Results: After PS matching, a total of 1535 patients were included 
(PANGAEA, n= 1163; PEARL, n= 372). The proportions of patients in the PANGAEA 
and PEARL cohorts with 3-month confirmed disability improvement were 14.6% and 
7.0%, respectively (p< 0.001). Similar results were seen for 6-month confirmed dis-
ability improvement (11.0% vs 6.2%; p< 0.001). The probability of 3-month confirmed 
disability improvement was significantly higher in PANGAEA compared with PEARL 
(175% increase; HR, 2.75; 95% CI, 1.82–4.15; p< 0.001). The corresponding value for 
6-month confirmed disability improvement was a 126% increase (2.26; 1.45–3.53; 
p< 0.001). Similar findings were found in subgroups of patients with at least 1 year of 
follow-up (3-month: 176% increase; 2.76, 1.80–4.22; p< 0.001; 6-month: 136% increase; 
2.36, 1.50–3.69; p< 0.001). cOnclusiOns: This comparison of real-world cohorts 
of patients with MS demonstrates that fingolimod treatment is associated with 
statistically significant increases in the probability of confirmed disability improve-
ment compared with BRACE.
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Objectives: BG-12 and Teriflunomide are the first two oral therapeutics for the 
treatment of Multiple Sclerosis. At the moment there is no direct comparison 
of these agents. The adjusted indirect comparison is a comparison of different 
therapies adjusted according to their direct comparison results against a common 
control, so that the strength of the randomised trials is preserved. MethOds: A 
Systematic literature search was conducted in the databases of Medline, Embase 
and Cochrane. Due to a lack of direct evidence an adjusted indirect comparison 
by Bucher in efficacy endpoints was performed. The risk of bias tool was used to 
assess the methodological quality of the included studies. Results: 339 studies 
were identified in a systematic literature search. Finally four RCTs were eligible in 
which 4861 patients had been randomized. All included studies have a low risk of 
bias. There were no significant heterogeneity between the included studies in the 
operationalization of the relevant endpoints for AIC. Adjusted Indirect comparisons 
could be performed in the endpoints annual relapse rate, percentage of relapse 
free patients and percentage of patients with EDSS progression. In the annual-
ized relapse rate BG-12 gains a statistically significant 44% risk reduction against 
Laquinimod (RR= 0,66 [0,52;0,85]) and 26% against Teriflunomide (RR= 0,74 [0,56;0,99). 
In no other endpoint the results were significant. cOnclusiOns: It can be assumed 
that the relapse risk under BG-12 is less than under Laquinimod or Teriflunomide. 
The possible superiority of BG-12 has to be checked with the help of further direct 
comparative RCTs.
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Objectives: The newly-introduced glatiramer acetate (GA; COPAXONE®) 40 mg/
ml three times a week maintains the known efficacy and safety of GA 20 mg/ml 
once-daily but requires around 200 fewer injections per year (60% fewer) for people 
treated for relapsing forms of multiple sclerosis (MS). An economic model with a 
five-year time horizon estimated the financial impact to the Spanish healthcare 
system of reduced switching from GA-based regimens to more expensive newly-
introduced first-line disease modifying therapies (DMTs) and the second-line 
DMTs. MethOds: The eligible population was based on 2014 Spanish MS inci-
dence rates, with the proportion receiving DMTs calculated using market research 
data. Medication costs were based on known Spanish prices, while treatment initia-
tion, administration and monitoring costs were calculated from published Spanish 
sources and Summary of Product Characteristics documentation. Switching rates 
and future treatment patterns were based on manufacturer’s projections. Results: 
An estimated 5,084 people with MS received GA 20 mg/ml once-daily in Spain in 
2014 (12.1% of those receiving DMTs) and were assumed to switch to more expen-
sive newly-introduced first-line and second-line DMTs at an annual rate of 8%. 
Assuming these people received GA 40 mg/ml three times a week instead, and – due 
to requiring fewer injections – switched at an annual rate of 5%, total expenditure 
on DMTs and related costs was reduced by between € 5.9 million and € 7.2 million 
annually, with savings totalling € 32.8 million over five years: a 21% reduction in total 
expenditure related to DMTs included in the model, compared with GA 20 mg/ml 
once-daily. Savings were primarily driven by lower acquisition costs of GA compared 
with other DMTs, and also from lower initiation, administration and monitoring 
requirements. cOnclusiOns: Introducing GA 40 mg/ml three times a week may 
limit switching from GA to more expensive newly-introduced first- and second-line 
DMTs, potentially generating cost savings.
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Objectives: The objective of this study was to estimate the incremental budget 
impact (BI) of utilizing perampanel to treat partial-onset seizures (POS) in patients 
who are 12 years of age and older in Russia. MethOds: The incremental BI was 
estimated by comparing the cost of POS seizures with and without perampanel. 
Direct (drugs, healthcare provider visits, emergency room visits, hospitalizations) 
and indirect (overall work impairment) costs were included. The model was devel-
oped from a societal perspective. The time horizon is five years. Costs are reported 
in rubles (RUB). Results: An estimated 351,582 patients ages 12 years and older 
are treated for POS in Russia each year. Approximately 53% are refractory (experi-
encing persistent seizures despite current treatment). The market share uptake of 
perampanel in POS patients is estimated to be 3%, 5%, 10%, 15% and 20%, in years 1 
to 5, respectively. During these five years, the adoption of perampanel is projected to 
increase overall costs by 305M, 510M, 1,022M, 1,537M and 2,055M RUB, respectively. 
Due to seizure reductions with perampanel, 27% of the drug cost increase (5,428M 
RUB) over 5 years is offset by the lower utilization of direct medical resources (RUB 
-25M) and lower overall work impairment (RUB -1,450M), yielding an overall BI of 
2.5% over 5 years. cOnclusiOns: With a budget impact of only 2.5% over a period of 
5 years and demonstrated efficacy benefits in refractory POS patients (63% median 
reduction in secondarily generalized seizures and 13% seizure freedom rate), per-
ampanel should be considered a valuable treatment.
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Objectives: To project the number and costs of relapses and escalations to second-
line therapy over 2 years for subcutaneous (SC) interferon beta (IFNβ )-1a (Rebif®), 
intramuscular (IM) IFNβ -1a, IFNβ -1b, and glatiramer acetate (GA) in the treatment of 
first-line relapsing-remitting multiple sclerosis (RRMS) from the perspective of the 
UK National Health Service (NHS). MethOds: A four-state (initial therapy, alternate 
first-line therapy, second-line therapy [natalizumab], and discontinuation) Markov 
model was constructed to simulate a cohort of 1,000 newly-diagnosed RRMS patients. 
Transition probabilities were based on real-world persistence data from the NHS 
and a patient treatment flow study. Risk of relapse was linearly interpolated based 
on 2-year data from a Cochrane Review network meta-analysis. The cost of a relapse 
was sourced from the literature and inflated to 2014 GBP. Drug acquisition costs were 
sourced from the British National Formulary. Administration costs were sourced from 
a NICE costing template. One-way sensitivity analyses were performed to test the 
robustness of the model results. Results: Treatment with SC IFNβ -1a is projected 
to avoid 94, 7, and 7 additional relapses compared with IM IFNβ -1a, IFNβ -1b, and GA, 
respectively, resulting in cost savings of £279,460, £20,877, and £20,877 over 2 years 
in a hypothetical cohort of 1,000 newly-diagnosed RRMS patients. Treatment with 
corticosteroid pulse and plasmapheresis may help in acute attacks of NMO. Further 
well designed, adequately powered studies are required in this context.
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Objectives: The cost-effectiveness of CAH screening (a state-level policy) was 
assessed by Yoo and Grosse (2009) using national incidence (NATL). Incidence of 
rare genetic diseases often varies geographically, however, it is likely that some 
state variation is due to sampling error. This research assesses the extent of the 
sampling error explanation through a series of simulations. MethOds: We obtained 
actual state-level incidence (ASI) for the 50 US states plus DC for 2006. For the 
simulation we assumed that state equaled national incidence and constructed a 
Beta distribution with alpha parameter equaling predicted state cases, and Beta 
parameter equaling state births minus predicted cases. We then ran a Monte Carlo 
simulation of 1000 iterations and calculated the proportion of iterations for which 
the incidence draw was more extreme than the ASI (i.e. draw > ASI if ASI > NATL or 
draw < ASI if ASI < NATL). Small numbers of iterations more extreme than the ASI 
are consistent with the ASI not equaling NATL. Extreme was defined as less than 5% 
of draws in the simulation less than the ASI (if ASI< NATL) or greater than the ASI 
(if ASI > NATL). Results: ASI per 1000 births ranged from 0 to .343 (median, .038). 
There were 21 states with ASI < NATL (including 13 values of 0) and 25 states with 
ASI > NATL. Of the 46 states reporting ASI, 21 (47%) had an “extreme” ASI by our 
definition. cOnclusiOns: State incidence appears to be “extreme” vs the national 
average in a large number of states and, therefore, does not seem to be explained 
by sampling error alone. As a difference in incidence may affect cost-effectiveness, 
further exploration using ASIs instead of a national average may be beneficial for 
directing state-level screening policy.
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Objectives: The research is to analyze social demographic characteristics and 
health service use nature of Parkinson’s disease in Korea by using Korean National 
Health Insurance Claims dataset (HIRA-NPS 2013), which is one of the secondary 
sources of health and medical treatment provided by reimbursement authority, 
and to measure a direct medical costs of Parkinson’s disease. MethOds: Patients 
with primary or secondary disease code for Parkinson’s Disease according to Korean 
Standard Classification of Disease (KICD-10 code : G20) are selected from National 
Patients Sample Dataset. The characteristics of age, sex, length of stay for inpatients, 
the number of outpatient visit and medical cost were analyzed based on the patient 
dataset extracted. SAS 9.2 (SAS Institute Inc., Cary, NC, USA) was used for statistical 
analysis. Results: The number of patients with Parkinson’s disease for the analysis 
was 4,137, and that of claims cases for 12 months was 34,259. The average age of 
the patients was 71.6 years old and the female patients composed 60.11%, which 
was about 1.5 times that of the male patients. The prevalence rate of Parkinson’s 
disease per 1,000 populations was 3.54 in 2013. Based on 1-year claims dataset, 
outpatient visit days were 9.83 and inpatient hospitalization days were 25.3. The 
annual direct medical costs were USD 487 for an outpatient and USD 10,429 for an 
inpatient. cOnclusiOns: As the result, the Parkinson’s disease is the economic 
burden in aging society in Korea. The limitation that the sample data used for 
the research is smaller than the raw data should be considered. Therefore further 
analysis on Parkinson’s disease in aging society is needed.
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Objectives: To estimate the prevalence of status epilepticus (SE), refractory status 
epilepticus (RSE), and super-refractory status epilepticus (SRSE) in five major European 
Union (5EU) markets (France, Germany, Italy, Spain, and the United Kingdom) using 
an incidence-survival model. MethOds: Yearly survival data for each SE etiology 
(acute symptomatic, progressive symptomatic, remote symptomatic, and idiopathic/
cryptogenic) were extracted from published research. Incident cases were calculated 
for each etiology beginning with 1995, based on market-specific published rates. 
Applying the survival proportions and incidence estimates to the model for each 
etiology, we calculated an overall estimate of the prevalence of SE. RSE and SRSE 
prevalent cases were assessed as proportions of the total number of prevalent SE 
cases using published values. Results: We estimated the prevalence of SE to be 
18.4 cases per 10,000 population in the 5EU, resulting in 590,264 cases in 2015 and 
increasing to 603,951 in 2024. The calculated prevalence ranged from 17.2 cases per 
10,000 (Germany) to 19.7 cases per 10,000 (Italy). The prevalence of RSE in the 5EU was 
4.5 per 10,000, resulting in 145,205 cases in 2015, increasing to 148,572 in 2024. SRSE 
prevalence in the 5EU was 1.8 per 10,000, resulting in 59,027 cases in 2015, increas-
ing to 60,395 in 2024. cOnclusiOns: To our knowledge, this is the first attempt to 
calculate the prevalence of SE and its subtypes for all ages in Europe. Estimating the 
prevalence of SE, RSE, and SRSE using population-based epidemiological methods is 
challenging because of the variability of SE disease definitions and the unpredictable 
nature of mortality due to SE. Our incidence-survival model provides an alternative 
and effective method to assess the prevalent population. Considering the high costs 
associated with treatment and hospitalization of SE, RSE, and SRSE patients, these 
estimates are necessary to quantify the burden of disease in Europe.
